Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus calmette-guerin vaccine
- Development stage
- Approved
- Lead developer
- Institut Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravesical, Percutaneous
01
Overview
The Bacillus Calmette–Guérin (BCG) vaccine is a live attenuated bacterial vaccine derived from a strain of *Mycobacterium bovis*. Originally developed over a century ago for the prevention of tuberculosis, it is now also a standard intravesical immunotherapy for non-muscle invasive bladder cancer. The vaccine's mechanism involves 'trained immunity,' where it epigenetically reprograms innate immune cells (such as monocytes and natural killer cells) to mount enhanced, non-specific responses against a broad spectrum of pathogens. Currently, the University of Birmingham is conducting the Phase IV STABILISE trial to evaluate whether BCG vaccination can reduce exacerbations in adults with chronic obstructive pulmonary disease (COPD) who are tuberculosis-negative.
- Brand names
- TICE BCGOncoTICEImmuCystBCG Vaccine AJVBCG Vaccine SSI
- Other names
- BCG vaccineBacillus Calmette-GuerinMycobacterium bovis BCG
02
Targets
αMβ2 (Integrin αMβ2)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)CLEC7A (Dectin-1)
Beyond the preview
Go deeper on bacillus calmette-guerin vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus calmette-guerin vaccine.